<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135069</url>
  </required_header>
  <id_info>
    <org_study_id>RAM-01</org_study_id>
    <nct_id>NCT01135069</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo</brief_title>
  <official_title>Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spear Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spear Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear
      Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not required
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Acne</measure>
    <time_frame>12 weeks</time_frame>
    <description>Counting of acne lesions both inflammatory and non-inflammatory</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Generic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of acne for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of acne for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment if acne for 12 weeks as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin microsphere 0.1%</intervention_name>
    <description>Treatment of acne vulgaris</description>
    <arm_group_label>Generic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brand Retin-A Micro tretinoin microsphere gel 0.1%</intervention_name>
    <description>Treatment of acne vulgaris</description>
    <arm_group_label>Brand</arm_group_label>
    <other_name>Retin-A Micro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo microsphere gel</intervention_name>
    <description>treatment of acne vulgaris</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy male and female children and adult

          -  Written and verbal informed consent must be obtained. Patients age 12 to 17
             (inclusive) must sign an assent for the study and a parent or a legal guardian must
             sign the informed consent.

          -  Women of child-bearing potential must be non-pregnant and non-nursing, and must be
             willing to avoid pregnancy during the course of the study and during the menstrual
             cycle following completion of their participation in the study.

          -  Able to refrain from the use of all other topical acne medications or antibiotics
             during the treatment period.

          -  Considered reliable and capable of understanding their responsibility and role in the
             study.

        Exclusion Criteria:

          -  Significant history or clinical evidence of auto-immune, cardiovascular,
             gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.

          -  Abnormal pre-existing skin condition which might affect the normal course of acne
             vulgaris (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders).

          -  Use topical acne therapy during the two week period prior to study initiation.

          -  Use of systemic retinoid treatment within six months prior to study initiation.

          -  Pregnant or breast-feeding.

          -  Serious psychological illness.

          -  Participation in any clinical research study during the 30 day period preceding study
             initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krunal Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moore Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moore Clinical Research</name>
      <address>
        <city>Land O Lakes</city>
        <state>Florida</state>
        <zip>34628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>May 28, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2014</results_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Generic</title>
          <description>Tretinoin Microsphere Gel 0.1%</description>
        </group>
        <group group_id="P2">
          <title>Brand</title>
          <description>Retin-A Micro 0.1%</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Microsphere Gel no active</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Generic</title>
          <description>Tretinoin Microsphere Gel 0.1%</description>
        </group>
        <group group_id="B2">
          <title>Brand</title>
          <description>Retin-A Micro 0.1%</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Microsphere Gel no active</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="205"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="480"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" spread="7.4"/>
                    <measurement group_id="B2" value="21" spread="8.1"/>
                    <measurement group_id="B3" value="19" spread="6.7"/>
                    <measurement group_id="B4" value="21" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Acne</title>
        <description>Counting of acne lesions both inflammatory and non-inflammatory</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Generic</title>
            <description>treatment of acne for 12 weeks
Percent change (reduction) in acne lesions was 74% reduction.</description>
          </group>
          <group group_id="O2">
            <title>Brand</title>
            <description>Treatment of acne for 12 weeks
Percent change (reduction) in acne lesions was 76% reduction</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment of acne for 12 weeks
Percent change (reduction) in acne lesions was 58% reduction</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Acne</title>
          <description>Counting of acne lesions both inflammatory and non-inflammatory</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74" spread=".05"/>
                    <measurement group_id="O2" value="-76" spread=".04"/>
                    <measurement group_id="O3" value="-58" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Generic</title>
          <description>Tretinoin Microsphere Gel 0.1%</description>
        </group>
        <group group_id="E2">
          <title>Brand</title>
          <description>Retin-A Micro 0.1%</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Microsphere Gel no active</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation</sub_title>
                <description>Tretinoin produces irritation</description>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="209"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>No unexpected problems.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>K.L. Spear M.D.</name_or_title>
      <organization>Spear Pharma</organization>
      <phone>239-433-3442</phone>
      <email>spear@spearpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

